Oats for Avenanthramides
Avenanthramides are a class of approximately 40 related phenolic alkaloids found uniquely in oats (Avena sativa) and a few wild oat relatives — nowhere else in the human food supply, including not in any other cereal grain (wheat, rice, barley, corn, rye, sorghum, or millet all lack them entirely). The three most abundant in commercial oats are avenanthramide A (Bp), B (Bf), and C (Bc), at typical concentrations of 4–40 mg per kg of oat grain depending on cultivar and growing conditions. They are anti-inflammatory through NF-kB inhibition, anti-itch through histamine-receptor and prostaglandin-pathway modulation (the mechanism behind the colloidal-oatmeal Aveeno topical preparations approved by the FDA for eczema), and antioxidant on a molar basis comparable to many flavonoids. Avenanthramide C in particular has been shown to inhibit vascular smooth muscle cell proliferation, suppress endothelial expression of adhesion molecules (VCAM-1, ICAM-1) implicated in early atherosclerosis, and reduce post-eccentric-exercise inflammation markers in human trials. This page traces the discovery history, the molecular mechanisms, the topical-dermatology evidence base, the emerging cardiovascular and exercise-recovery data, and the question of whether dietary oat intake delivers a meaningful systemic dose.
Table of Contents
- Chemistry and Discovery (Dimberg 1993)
- Why Only Oats Make Them — The Avenanthramide Biosynthetic Pathway
- The NF-kB Anti-Inflammatory Mechanism
- Colloidal Oatmeal — Topical Eczema and Atopic Dermatitis
- Vascular Effects and Endothelial Function
- Post-Exercise Inflammation and Recovery
- Bioavailability — Does Eating Oats Deliver a Systemic Dose?
- Cultivar Variation and Stress-Induced Synthesis
- Topical Skincare Beyond Eczema
- Cautions
- Key Research Papers
- Connections
Chemistry and Discovery (Dimberg 1993)
The phenolic alkaloid class now called avenanthramides was first isolated and structurally characterized by Lena Dimberg and colleagues at the Swedish University of Agricultural Sciences in 1992–1993 (Dimberg, Theander, Lingnert, Cereal Chemistry 70:637). They identified 25 related compounds in oat grain extracts, all sharing a common skeleton: a hydroxycinnamic acid (typically caffeic, ferulic, or p-coumaric acid) linked via an amide bond to an anthranilic acid derivative (typically 5-hydroxyanthranilic acid or 4-hydroxyanthranilic acid). The hybrid structure — part hydroxycinnamic acid, part aromatic amine — is unusual and is the source of their unique pharmacology.
The three avenanthramides present at the highest concentrations in commercial cultivars are:
- Avenanthramide A (also called Bp or 2p) — the p-coumaroyl-5-hydroxyanthranilate
- Avenanthramide B (also called Bf or 2f) — the feruloyl-5-hydroxyanthranilate
- Avenanthramide C (also called Bc or 2c) — the caffeoyl-5-hydroxyanthranilate — the most biologically active in most published assays
Total avenanthramide content in commercial oat groats typically ranges from 4 to 40 mg/kg dry weight, with substantial variation across cultivars and growing seasons. The Swedish breeding line "Sang" reaches over 100 mg/kg under ideal conditions; experimental lines stress-induced with crown rust fungus reach over 250 mg/kg.
By comparison, a search across wheat, barley, rye, rice, corn, sorghum, millet, quinoa, amaranth, buckwheat, and teff has identified essentially zero avenanthramide content in any of these grains. Their presence is one of the few biochemical features that makes oats genuinely unique in the human diet rather than just a quantitative variation on a generic cereal-grain profile.
Why Only Oats Make Them — The Avenanthramide Biosynthetic Pathway
The avenanthramide biosynthetic pathway requires the enzyme hydroxycinnamoyl-CoA:hydroxyanthranilate N-hydroxycinnamoyltransferase (HCBT), which catalyzes the amide-bond formation between activated hydroxycinnamic acid (as the CoA thioester) and a hydroxyanthranilate aromatic amine. The HCBT gene is present in oats and has been cloned and characterized (Yang Q et al., Phytochemistry 2004); it is absent or non-functional in other cereal grains.
The pathway appears to function as a phytoalexin defense response — avenanthramides are induced by pathogen attack, particularly by the crown rust fungus Puccinia coronata. Infected oat tissue accumulates 10–100-fold higher avenanthramide concentrations than uninfected tissue, and the compounds are mildly antifungal in vitro. This is consistent with the broader pattern of phytoalexin metabolism in plants, where stress-induced secondary metabolites accumulate in defensive responses. The implication for the consumer is that oats grown under organic conditions, with more exposure to natural pathogen pressure and less prophylactic fungicide use, often have higher avenanthramide content than conventionally grown oats — though the variation across cultivars typically exceeds the variation across growing methods.
The presence of avenanthramides in commercial oats appears to be entirely accidental from a human-health perspective — oat breeders did not select for these compounds until very recently. Modern Swedish, Canadian, and U.S. oat breeding programs are now actively selecting high-avenanthramide cultivars for nutritional value, but the bulk of the commercial oat supply is from older cultivars selected primarily for yield, lodging resistance, and beta-glucan content.
The NF-kB Anti-Inflammatory Mechanism
The dominant anti-inflammatory mechanism of avenanthramides operates through suppression of NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells), the master transcription factor that drives expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Sur et al. 2008 (Arch Dermatol Res 300:569) and Guo et al. 2008 (Mol Nutr Food Res 52:S52) demonstrated, in parallel cell-culture studies of human keratinocytes and human aortic endothelial cells respectively, that avenanthramide C at 1–100 micromolar concentrations dose-dependently inhibits TNF-alpha-induced NF-kB nuclear translocation. The downstream consequences include:
- Reduced expression of intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) on endothelial cells — the molecules that mediate early monocyte recruitment to nascent atherosclerotic lesions.
- Reduced expression of pro-inflammatory cytokines IL-6, IL-8, and TNF-alpha by activated keratinocytes and macrophages.
- Reduced cyclooxygenase 2 (COX-2) expression and downstream prostaglandin E2 production — a mechanism shared with non-steroidal anti-inflammatory drugs (NSAIDs).
- Reduced inducible nitric oxide synthase (iNOS) expression and reactive nitrogen species production.
This pattern of NF-kB suppression is shared with the polyphenol class as a whole (curcumin, resveratrol, EGCG, quercetin) but the specific structural features of avenanthramides — the hybrid hydroxycinnamic-acid-amide architecture — appear to produce a particularly tight binding to upstream kinases in the NF-kB activation pathway.
The clinical translation of NF-kB suppression remains the central challenge: in-vitro effects at 1–100 micromolar do not necessarily translate to in-vivo benefits at the typical plasma concentrations achievable from dietary oat intake (which peak in the nanomolar to low-micromolar range; see Bioavailability section).
Colloidal Oatmeal — Topical Eczema and Atopic Dermatitis
The single clearest clinical application of avenanthramides is topical. Colloidal oatmeal — finely ground whole-oat flour suspended in a vehicle — has been used as a topical anti-pruritic for centuries, formalized in U.S. regulatory frameworks in 2003 when the FDA approved colloidal oatmeal as a Category I skin protectant for the treatment of atopic dermatitis and other pruritic skin conditions (21 CFR 347.10). The Aveeno line of products (Johnson & Johnson) was the original commercial preparation; numerous generic equivalents are now available.
The active components in colloidal oatmeal are a mix of beta-glucan (which forms a hydrating film), saponins (which provide mild cleansing), and the avenanthramides (which provide the anti-inflammatory and anti-pruritic effect). Reynertson et al. 2015 (J Drugs Dermatol 14:43) reviewed the in-vitro and clinical evidence and concluded that the anti-inflammatory benefit is primarily driven by the avenanthramide fraction, with beta-glucan playing a secondary moisturizing role.
Clinical trials in atopic dermatitis (Fowler et al. 2014, J Drugs Dermatol 13:1180; Lisante et al. 2017, J Drugs Dermatol 16:671) consistently show reduced itching, erythema, and SCORAD scores with daily application of colloidal-oatmeal-containing lotions, comparable to mid-potency topical corticosteroids on some endpoints and with no steroid-class side effects (skin atrophy, telangiectasia, HPA-axis suppression). The effect is generally most pronounced for mild-to-moderate atopic dermatitis; severe cases still typically require topical immunomodulators or corticosteroids.
The topical-dermatology indication has been extended to:
- Chemotherapy- and radiation-induced dermatitis — multiple oncology supportive-care guidelines recommend colloidal-oatmeal preparations as first-line topical care for cutaneous toxicity from EGFR inhibitors, radiation therapy, and chemotherapy-induced hand-foot syndrome.
- Pediatric atopic dermatitis — widely used in infants and young children where steroid sparing is particularly desirable.
- Pruritus of dry skin in elderly patients — xerosis-related itching, often refractory to simple emollients, responds well to colloidal-oatmeal preparations.
- Post-procedural skin care — after laser resurfacing, chemical peels, and other dermatologic procedures.
Vascular Effects and Endothelial Function
The most active emerging area of avenanthramide research is cardiovascular. Liu, Nair, and colleagues at Tufts and the USDA Beltsville center have published a series of mechanistic and clinical papers showing avenanthramide effects on vascular smooth muscle cells, endothelial cells, and post-prandial markers of vascular inflammation:
- Avenanthramide C inhibits human aortic smooth muscle cell proliferation at low-micromolar concentrations (Nie et al. 2006, Atherosclerosis 186:260) — relevant because smooth muscle cell proliferation in the intima is a key step in atherosclerotic plaque formation.
- Avenanthramides suppress monocyte adhesion to TNF-alpha-stimulated human aortic endothelial cells (Guo et al. 2008) — relevant because monocyte adhesion is the earliest detectable event in atherosclerosis initiation.
- Avenanthramide-enriched oat extract supplementation in postmenopausal women reduced plasma adhesion molecule levels and improved flow-mediated vasodilation, a surrogate for endothelial function (Liu et al. study at Tufts, summarized in Meydani 2009 Nutr Rev 67:731).
- In a small randomized trial in healthy adults, supplementation with avenanthramide-enriched oat extract reduced inducible nitric oxide synthase mRNA expression in mononuclear cells, consistent with reduced systemic inflammatory tone.
The trial evidence remains thin compared to the well-established beta-glucan-cholesterol data, but the mechanistic story is strong enough that avenanthramides are now an active target for fortification studies — some commercial oat-based supplements contain concentrated avenanthramide extracts at 5–10x the concentration of native oat groats.
Post-Exercise Inflammation and Recovery
Koenig et al. 2014 (J Diet Suppl 11:155) tested oral avenanthramide supplementation (9.2 mg avenanthramide enriched ready-to-eat cereal, daily for 8 weeks) versus a control cereal in 12 postmenopausal women undergoing a single bout of eccentric quadriceps exercise. The avenanthramide arm showed:
- Significantly lower plasma IL-6 at 1 and 4 hours post-exercise
- Significantly lower plasma C-reactive protein at 24 hours post-exercise
- Significantly lower neutrophil counts at 24 hours post-exercise
- Trends toward lower delayed-onset muscle soreness (DOMS) ratings by visual analog scale at 24 and 48 hours
The trial was small but the effect sizes were meaningful and consistent across multiple inflammatory markers. The implication is that habitual whole-oat intake may modestly attenuate exercise-induced inflammation — an effect with parallels to tart cherry juice, beetroot, and other polyphenol-rich foods marketed for recovery.
For elite athletes and serious recreational athletes, the practical takeaway is that incorporating ~1 cup of cooked whole oats daily into the diet may contribute marginally to inflammation management without the trade-offs of suppressing the adaptive inflammatory response that drives training adaptation (the well-documented problem with high-dose NSAID use during training cycles).
Bioavailability — Does Eating Oats Deliver a Systemic Dose?
The bioavailability question is critical for translating in-vitro cell-culture findings to in-vivo clinical effects. Chen et al. 2007 (J Nutr 137:1375) administered a single dose of avenanthramide-enriched oat extract (300 mg total avenanthramides A, B, and C) to 6 healthy adults and measured plasma concentrations over 10 hours. Plasma avenanthramide A peaked at ~110 nanomolar at 2 hours; avenanthramide B at ~80 nM at 2 hours; avenanthramide C at ~110 nM at 2 hours. All three returned to near baseline by 10 hours.
The dose was approximately 10x what a single serving of typical oat porridge would provide, suggesting that a normal serving of oats produces plasma avenanthramide concentrations in the low-nanomolar range — well below the 1–100 micromolar concentrations used in most cell-culture mechanistic studies. The systemic dose from daily oat consumption is therefore likely too low to produce direct vascular endothelial effects equivalent to the in-vitro observations.
Several caveats moderate this conclusion:
- Repeated daily intake may produce a steady-state plasma concentration higher than single-dose pharmacokinetics suggest, particularly if there are saturable elimination pathways.
- Tissue concentrations in the gut epithelium — the first site of exposure — are likely much higher than plasma, supporting a possible local anti-inflammatory effect in the intestinal mucosa relevant to inflammatory bowel disease research.
- Avenanthramide metabolites (conjugated with glucuronic acid and sulfate in the liver) may retain biological activity and circulate at higher concentrations than the parent compounds.
- For topical applications, the in-vitro concentrations are directly relevant because topical penetration delivers high local concentrations to skin keratinocytes — this is the strongest case for direct mechanism-to-effect translation.
The honest summary is: topical applications of colloidal oatmeal are well-supported by both mechanism and clinical trials; dietary intake of whole oats may provide modest systemic anti-inflammatory benefit but the trial evidence is still thin and the calculated systemic doses are at the low end of biologically active concentrations.
Cultivar Variation and Stress-Induced Synthesis
Total avenanthramide content varies more than 10-fold across commercial oat cultivars. The Swedish breeding programs in Lund have identified several lines with consistently high avenanthramide content (notably "Belinda" and "Sang"); Canadian and U.S. breeding programs are following suit. Some commercial brands (Bob's Red Mill, Trader Joe's organic steel-cut) report higher-than-average avenanthramide content based on third-party testing but do not generally provide quantitative label information.
Stress conditions during the growing season — particularly mild crown rust pressure, ozone exposure, and moderate drought — induce avenanthramide accumulation as part of the plant defense response. This is one of several reasons that organically grown crops, with their greater exposure to natural pathogen and environmental pressure, often have higher polyphenol content than conventionally grown equivalents.
From a practical consumer standpoint, the inability to compare cultivars based on label information means that buying organic, whole-form, minimally processed oats is the simplest path to higher avenanthramide intake without trying to chase specific cultivars.
Topical Skincare Beyond Eczema
Beyond the FDA-recognized atopic dermatitis indication, colloidal oatmeal is widely used in:
- Sunburn relief — the anti-inflammatory and anti-pruritic properties make cool oatmeal compresses or baths a long-standing folk remedy for sunburn that has substantial mechanistic support.
- Poison ivy/oak dermatitis — oatmeal baths reduce itching and inflammation from urushiol-induced contact dermatitis.
- Insect bites and stings — localized application reduces itching and erythema.
- Postpartum perineal care — oatmeal sitz baths are used in some hospital protocols.
- Eyelid dermatitis — the safety profile permits use in the periocular region where corticosteroids are problematic.
- General skincare for sensitive skin types — cleansers and moisturizers containing colloidal oatmeal are tolerated by most rosacea, perioral dermatitis, and seborrheic dermatitis patients.
The DIY oatmeal bath approach — 1 cup colloidal oatmeal (food-processor-pulverized rolled oats are an acceptable substitute) in a lukewarm bath for 15–20 minutes — provides equivalent topical exposure to commercial products at a fraction of the cost and is appropriate for use on infants, pregnant women, and elderly patients with concerns about commercial-product ingredients.
Cautions
- Topical sensitivity is rare but possible — a small minority of users develop contact dermatitis from oat-derived topical products, sometimes attributed to oat proteins (avenins) themselves or to vehicle ingredients. Patch testing before extended use on a new product is sensible for individuals with known cosmetic allergies.
- Dietary avenanthramide intake is not a substitute for established anti-inflammatory therapies — for conditions like rheumatoid arthritis, inflammatory bowel disease, or systemic vasculitis, oat intake should complement but not replace standard treatments.
- Bioavailability data are limited — systemic effects from dietary oat intake are likely modest and the strongest evidence remains for topical applications.
- Concentrated avenanthramide supplements are commercially available but lack the body of safety data that exists for whole-food oat consumption; mega-dose supplementation of any plant polyphenol has the potential for off-target effects and pro-oxidant behavior at very high concentrations.
- Concomitant medications — NF-kB suppression overlaps with mechanisms targeted by some immunomodulating drugs; clinically meaningful interactions from dietary oat intake have not been reported but caution is reasonable for patients on biologic immunosuppressants.
Key Research Papers
- Dimberg LH, Theander O, Lingnert H, avenanthramides — a group of phenolic antioxidants in oats (Cereal Chemistry 1993;70:637-41) — PubMed: Dimberg 1993
- Meydani M, potential health benefits of avenanthramides of oats (Nutr Rev 2009;67:731-5) — PubMed PMID 19751199
- Sur R, Nigam A, Grote D, Liebel F, Southall MD, avenanthramides polyphenols from oats exhibit anti-inflammatory and anti-itch activity (Arch Dermatol Res 2008;300:569-74) — PubMed PMID 18461339
- Guo W, Wise ML, Collins FW, Meydani M, avenanthramides inhibit proliferation of human aortic smooth muscle cells in vitro (Free Radic Biol Med 2008;44:415-29) — PubMed: Guo aortic smooth muscle
- Liu L, Zubik L, Collins FW, Marko M, Meydani M, the antiatherogenic potential of oat phenolic compounds (Atherosclerosis 2004;175:39-49) — PubMed PMID 15186945
- Nie L, Wise ML, Peterson DM, Meydani M, avenanthramide a polyphenol from oats inhibits vascular smooth muscle cell proliferation and enhances nitric oxide production (Atherosclerosis 2006;186:260-6) — PubMed: Nie avenanthramide
- Koenig RT, Dickman JR, Kang CH, Zhang T, Chu YF, Ji LL, avenanthramide supplementation attenuates eccentric exercise-inflicted blood inflammatory markers in women (Eur J Appl Physiol 2014;114:2305-13) — PubMed PMID 24237191
- Reynertson KA, Garay M, Nebus J, Chon S et al., anti-inflammatory activities of colloidal oatmeal contribute to the effectiveness of oat in treatment of itch associated with dry irritated skin (J Drugs Dermatol 2015;14:43-8) — PubMed PMID 25607907
- Chen CY, Milbury PE, Collins FW, Blumberg JB, avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats (J Nutr 2007;137:1375-82) — PubMed: Chen bioavailability
- Chen CY, Milbury PE, Kwak HK, Collins FW, Samuel P, Blumberg JB, avenanthramides and phenolic acids from oats are bioavailable and act synergistically with vitamin C to enhance hamster and human LDL resistance to oxidation (J Nutr 2004;134:1459-66) — PubMed PMID 15173415
- Fowler JF Jr, Nebus J, Wallo W, Eichenfield LF, colloidal oatmeal formulations as adjunct treatments in atopic dermatitis (J Drugs Dermatol 2012;11:804-7) — PubMed: Fowler colloidal oatmeal
- Tripathi V, Singh A, Ashraf MT, avenanthramides of oats — medicinal importance and future perspectives (Pharmacogn Rev 2018;12:66-71) — PubMed: Avenanthramides review